Simtuzumab

Simtuzumab

Simtuzumab

Monoclonal antibody

Simtuzumab (INN; formerly GS 6624) is a humanized monoclonal antibody designed for the treatment of fibrosis.[1] It binds to LOXL2 and acts as an immunomodulator.[2] In January 2016, Gilead Sciences terminated its Phase 2 clinical study in patients with idiopathic pulmonary fibrosis (IPF) due to lack of efficacy.[3]

Quick Facts Monoclonal antibody, Type ...

References

  1. [1]
    Statement On A Nonproprietary Name Adopted By The USAN Council - Simtuzumab, American Medical Association.
  2. [2]
    World Health Organization (2012). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 107" (PDF). WHO Drug Information. 26 (2).
  3. [3]
    "Gilead Terminates Phase 2 Study of Simtuzumab in Patients With Idiopathic Pulmonary Fibrosis". Gilead. 5 January 2016.


Stub icon

This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it.
Share this article:

This article uses material from the Wikipedia article Simtuzumab, and is written by contributors. Text is available under a CC BY-SA 4.0 International License; additional terms may apply. Images, videos and audio are available under their respective licenses.